The modern antiretroviral treatment of human immunodeficiency virus (HIV-1) infection has
considerably lowered the incidence of opportunistic infections. With the exception of the …

Human immunodeficiency virus-type 1 (HIV-l) infection is the most common preventable and
treatable cause of neurocognitive impairment in individuals under age 50 years. Although …

HIV-associated neurocognitive disorder (HAND) remains a common cause of cognitive
impairment and persists in 15–55% of HIV+ individuals in the combination antiretroviral …

Human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) affects
roughly half the HIV-positive population. The symptoms of cognitive slowing, poor …

HIV-1 infiltrates the central nervous system (CNS) during the initial infection and thereafter
plays a persistent role in producing CNS dysfunction as the disease progresses. HIV …

The introduction of combination antiretroviral treatment (cART) has significantly reduced the
mortality secondary to opportunistic infections in HIV patients by restoring the immune …

The introduction of combined antiretroviral therapy (cART) has dramatically reduced the risk
of central nervous system opportunistic infection and severe dementia secondary to HIV …

In the era of highly active antiretroviral therapy (HAART), HIV-1-associated neurocognitive
disorder (HAND) continues to be a common and significant morbidity among individuals …

With the introduction of combination antiretroviral therapy AIDS dementia complex or HIV-
associated dementia, as it was termed later, largely disappeared in clinical practice …

The spectrum of HIV-associated neurocognitive disorder (HAND) has been dramatically
altered in the setting of widely available effective antiretroviral therapy (ART). Once …